Search

Displaying results 5801 - 5810 of 10000 in total
  1. Drug

    Anti-SARS-CoV-2 REGN-COV2

    go.drugbank.com/drugs/DB15691
    Investigational

    including contacts of an infected individual. … [L14306] Clinical trials for this drug started on June 11, 2020.

  2. Drug

    Xylazine

    go.drugbank.com/drugs/DB11477
    InvestigationalVet approved

    Xylazine is a clonidine analog used as a non-opioid tranquilizer in veterinary medicine and as an emetic, especially in cats. … [L42675] Xylazine is sometimes used as an adulterant and combined with opioids and recreational drugs; however, it has no antidote, and the use of [naloxone] has no effect on xylazine.[L42675,L42680]

  3. Drug

    NPS-2143

    go.drugbank.com/drugs/DB05695
    Experimental

  4. Drug

    N4-Hydroxycytidine

    go.drugbank.com/drugs/DB15660
    Experimental

    [A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. … [A193011] In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.

    Synonyms: 4-N-Hydroxycytidine, N(4)-Hydroxycytidine
  5. Drug

    Dihydromorphine

    go.drugbank.com/drugs/DB01565
    ExperimentalIllicit

    A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]

  6. Drug

    Marimastat

    go.drugbank.com/drugs/DB00786
    Investigational

    Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. … As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.

  7. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical

  8. Drug

    Vercirnon

    go.drugbank.com/drugs/DB15250
    Investigational

    It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). … Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD.

    International brands: Traficet-EN
  9. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

  10. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.